Patent · US Expired

Cell that expresses a sulfatase and a formylglycine generating enzyme

US8227212B2 · kind B2 · utility

22Cited by

4References

22Claims

0Family size

Assignee

SHIRE HUMAN GENETIC THERAPIES, INC. · US

Inventors

Kurt von Figura · Göttingen, DE
Bernhard Schmidt · Neunkirchen, DE
Thomas Dierks · Göttingen, DE
Michael Heartlein · Boxborough, US
Maria Pia Cosma · Barcelona, ES
Andrea Ballabio · Napoli, IT

Key dates

Filing date	Feb 10, 2004
Grant date	Jul 24, 2012
Priority date	—
Expiry date	Jan 2, 2026

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to methods and compositions for the diagnosis and treatment of Multiple Sulfatase Deficiency (MSD) as well as other sulfatase deficiencies. More specifically, the invention relates to isolated molecules that modulate post-translational modifications on sulfatases. Such modifications are essential for proper sulfatase function.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.